Seattle-based Alpenglow Biosciences announced a partnership with PathNet to bring its 3D microscope technology into clinical pathology labs to modernize diagnostics for prostate and bladder cancers.
Alpenglow, which spun out of the University of Washington in 2018, has developed tools that quickly create multi-dimensional images from biological tissue and apply AI-trained algorithms to analyze samples. The technology is already used in academic and pharmaceutical research but moving into clinical use requires additional rigor and regulatory validation. “People’s lives are depending on it,” CEO and co-founder Dr. Nick Reder said. “So there’s a lot more regulatory compliance and validation that needs to be done.”
The partnership with PathNet could enable more informative cancer diagnoses for patients by using 3D imaging and AI analysis to better assess disease risk and treatment response.